Aadel A. Chaudhuri
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (32)
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2026
STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.
Year:
2026
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2025
Figures showing the CONSORT diagram, clonal hematopoiesis prevalence, the SNV score model, mid-chemoradiation ctDNA analysis, radiomic model robustness, pre-chemoradiation prognostic factors, association of clonal hematopoiesis with outcomes, and association of the CIRI-LCRT model with progression-free survival.
Year:
2025
The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534
Year:
2025
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA + ) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA + EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA + EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months ( P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months ( P = 0.003) for PSMA + EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA + EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA + EV was predictive of benefit from SABR ( P = 0.012). Conclusions: PSMA + EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA + EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.
Year:
2025
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Year:
2025
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.
Year:
2025
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (51)
Oliver Sartor
Tulane University School of Medicine
AeRang Kim
Professor of Pediatrics
George Washington University
Heath Skinner
Professor & Chair
University of Pittsburgh
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
David Chen
Assistant Professor
Washington University in Saint Louis School of Medicine
Russell Taylor Sundby
Assistant Professor
Thomas Jefferson University
Sean Park
Professor
Mayo Clinic Rochester
Phuoc T. Tran
University of Maryland
Aaron Newman
Associate Professor
Stanford University
Yufei Liu
Assistant Clinical Professor
City of Hope
Jin Zhang
Associate Professor
Washington University in St. Louis
Paul Jones
Washington University in St. Louis
Everett J. Moding
Stanford University
Ross A Okimoto
University of California
Ruijiang Li
Associate Professor
Stanford University
James Zou
Stanford University
Jeffrey Szymanski
Assistant Professor
Mayo Clinic Minnesota
Zhenqin Wu
Assistant Professor
The University of Hong Kong
Jace Webster
Full Specialist
University of California, San Francisco
Tej D. Azad
Johns Hopkins University School of Medicine
Arash Ash Alizadeh
Professor of Medicine
Stanford University School of Medicine
Maximilian Diehn
Professor
Stanford University
Piet Ost
Ghent University
Kavitha Ramchandran
Clinical Associate Professor
Stanford University
Peter Harris
Staff Scientist
Washington University in St. Louis
Jacob Orme
Assistant Professor
Mayo Clinic
Angela C. Hirbe
Washington University School of Medicine
Andrea Gross
Associate Professor
Cincinnati Children's Hospital Medical Center
Matthew E. Spector
University of Pittsburgh Medical Center
Steven Lin
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Heather Wakelee
Professor
Stanford University
Jack Shern
Head, Tumor Evolution and Genomics Section
National Institutes of Health
Pradeep Chauhan
Assistant Professor
Mayo Clinic
Seema Nagpal
-
Sidharth V. Puram
Washington University School of Medicine
David Kurtz
Assistant Professor
Stanford University
Fabrice Lucien
Assistant Professor
Mayo Clinic Minnesota
Jose P. Zevallos
University of Pittsburgh Medical Center
Russell K. Pachynski
Washington University School of Medicine
Billy Loo
Professor
Stanford University
Trever Bivona
Professor
University of California, San Francisco
John S A Chrisinger
Washington University in St. Louis
Mohammed Abuul Usmani
Senior Scientist
Washington University in St. Louis
Michael F. Gensheimer
Stanford University School of Medicine
Robert Ferris
UPMC Endowed Professor
University of Pittsburgh School of Medicine
Carina A Dehner
Assistant Professor
University of Pennsylvania
Christopher A Maher
Washington University in St. Louis
Wade Thorstad
Professor
Washington University School of Medicine
Mohammad Shahrokh Esfahani
Assistant Professor
Stanford University
Amy Armstrong
Associate Professor in Pediatrics
Washington University Physicians
Make your next move.
Prepare your application
Review drafts before you send them.